Perspectum

Perspectum is an innovative company pushing the frontier of personalized medicine through our advanced non-invasive imaging portfolio. Working across the obesity, MASH and metabolic disease space, our best-in-class precision health technology provides sponsors with tangible insights into the mechanisms and benefits of their treatments. Working across the entire development pipeline, we support sponsors to differentiate their treatments by allowing them to see and quantify more than ever before.

Hep Mag

Hep magazine and HepMag.com are the go-to sources for educational and social support for people living with liver diseases like hepatitis C, hepatitis B, hepatitis A and NASH. Launched in 2010, the website is devoted to combating the stigma and isolation surrounding liver diseases, and offers news, in-depth reporting, educational tools, care resources, and peer-to-peer networking.

Gubra

Ascenian Consulting

Ascenian is a global market access company in the field of price and reimbursement for new pharmaceutical treatments and medical devices. Identifying the right evidence to support reimbursement and price decision makers is the core business of Ascenian. We are located in the US and Europe.

Hepatoma Research

Hepatoma Research is an international peer-reviewed, gold open access, online academic journal founded by OAE Publishing Inc. (www.oaepublish.com) in April 2015. The journal aims to provide the best academic exchange platform in the field of liver cancer, including its occurrence, development, diagnosis, and treatment. The coverage also extends to other basic and clinical studies related to surgery, internal medicine, cell biology, pathology, pathophysiology, immunology, genetics, pharmacology, etc. The journal is indexed in ESCI, Embase, Scopus and CAS, will get the first IF in June 2024. Visit our website (https://www.oaepublish.com/hr) to learn more.

TNO

TNO is a research and technology innovation institute which drives biomedical, technological and social innovations in collaboration with knowledge institutes, industrial partners and government authorities. Multidisciplinary teams of top scientists and technical experts enable us to model, mimic and measure infant health and disease risk. We connect experimental and clinical studies with innovative technologies to identify new biomarkers for health and disease, as well as substantiate the health benefit of compounds. Together, we can make a contribution to future health.

Somalogic

SomaLogic is catalyzing drug research and development and biomarker identification as a global leader in proteomics technology. With a 55 microliter plasma or serum sample, SomaLogic can run 11,000 protein measurements, covering more than a third of the approximately 20,000 proteins in the human body.

Echosens

A pioneer in its field, Echosens significantly changed the practice of liver diagnosis with FibroScan®, the non-invasive gold standard solution for comprehensive management of liver health.
FibroScan® is recognized worldwide as the reference for liver fibrosis and liver steatosis assessment with more than 4 200+ peer-reviewed publications and 180+ international guidelines.
Echosens has made FibroScan® available in over 100+ countries enabling millions of liver examinations worldwide.

CureDiab

CureDiab is a spin-off from the German Diabetes Center, was established in 2021, and has obtained seed financing. The company operates research labs and develops a first-in-class approach for MASH therapy using novel modulators of the GABA-A receptor. Hepatoprotective and anti-fibrotic activity of the patented lead compounds HK1,3 has been demonstrated, with a dual action on both hepatocytes and stellate cells.